ESSA Pharma Inc. (“ESSA,” or the “Company”) (NASDAQ: EPIX) announces that it has entered into a definitive agreement (the “Business Combination Agreement”) with XenoTherapeutics, Inc. (“Xeno”), a non-profit biotechnology company, under which Xeno will acquire (the “Transaction”) all of the issued and outstanding common shares of ESSA (the “Common Shares”). XOMA Royalty Corporation (“XOMA Royalty”) (NASDAQ: XOMA), the biotechnology royalty aggregator, is acting as the structuring agent and will provide financing to Xeno for this Transaction.
Read the full article: ESSA Pharma Inc. Announces Definitive Agreement to Be Acquired by XenoTherapeutics, Inc. //
Source: https://www.prnewswire.com/news-releases/essa-pharma-inc-announces-definitive-agreement-to-be-acquired-by-xenotherapeutics-inc-backed-by-xoma-royalty-corporation-in-all-cash-transaction-302504214.html